NEW YORK – Innova Medical Group and iXensor said Thursday they have reached a distribution deal covering Europe for the Phronesia Smart Ovulation Test, an Innova-branded assay using iXensor's technology.
Pasadena, California-based Innova is adding the urine-based test to its Phronesia self-testing portfolio and launching the Phronesia Smart Ovulation Test in France followed by a launch elsewhere in Western Europe, the United Kingdom, and then across Europe.
Xavier Guerin, president of Innova's European operations, said in a statement that it and iXensor will partner on development of the ovulation test "with a fully integrated hardware, app, and cloud solution, all being manufactured in a cost-effective manner."
Innova, a wholly owned subsidiary of Pasaca Capital, develops screening and diagnostic tests. Taipei City, Taiwan-based iXensor develops smartphone-integrated technology for self-testing and point-of-care testing.